AC	Adenocarcinoma
ATRA	All-Trans Retinoic Acid
AMI-1	Arginine Methyltransferase Inhibitor 1
ATO	Arsenic Trioxide
AZA	Azathioprine
CO	Carbon Monoxide
CR	Complete Response
COX-2	Cyclooxygenase-2
DAPK	Death-Associated Protein Kinase
DNA DSB	DNA Double Strands Break
DNMT	DNA Methyltransferase
EGFR	Epidermal Growth Factor Receptor
FDA	Food and Drug Administration
HDI(s)	HDAC Inhibitors
HATs	Histone Acetyltransferases
HDACs	Histone Deacetylases
HDI	Histone Deacetylases Inhibitors
HDMs	Histone Demethylases
KDMs	Histone Lysine Demethylases
KMTs	Histone Lysine Methyltransferases
HMTs	Histone Methyltransferases
HLA	Human Leukocyte Antigen
ICI	Immune Checkpoint Inhibitor
IL	Interleukins
IARC	International Agency for Research on Cancer
ICAM-1	Intracellular Adhesion Molecule-1
LCC	Large Cell Cancer
lncRNAs	Long Non-Coding RNAs
LSD1	Lysine Specific Demethylase
MAGEA3	Melanoma-Associated Antigen A3
MCP-1	Monocyte Chemotactic Protein-1
MDS	Myelodysplastic Syndromes
MHC	Major Histocompatibility Complex
MICA	MHC Class I Chain-Related Molecules
mRNA	Micro RNA
MUC1	Mucinous Glycoprotein-1
NNK	Nicotine-Derived Nitrosamine Ketone
NOx	Nitrogen Oxides
ncRNAs	Non-Coding RNAs
NSCLC	Non-Small Cell Lung Carcinoma
PR	Partial Response
PM	Particulate Matter
P2RD	Phase 2 Suitable Dose
PTMs	Post-Translational Modifications
PFS	Progression-Free Survival
PRMT5	Protein Arginine Methyltransferase 5
ROS	Reactive Oxygen Species
RFS	Relapse-Free Survival
RECIST	Response Evaluation Criteria in Solid Tumours
SCLC	Small Cell Lung Cancer
SCC	Squamous Cell Carcinoma
SAHA/Vorinostat	Suberoylanilide Hydroxamic Acid
SO2	Sulphur Dioxide
TSA	Trichostatin A
TSG	Tumour Suppression Genes
TKI	Tyrosine Kinase Inhibitor
VEGF	Vascular Endothelial Growth Factor
abb	ddd
AC	Adenocarcinoma